Evaluation of iron overload by cardiac and liver T2* in β-thalassemia: Correlation with serum ferritin, heart function and liver enzymes

Hengameh Khadivi Heris1, Babak Nejati2, Khatereh Rezazadeh1, Hossein Sate4, Roya Dolatkhah2, Zohreh Ghoreishi4, Ali Esfahani4

1Department of Internal Medicine, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
2Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3Nutrition Research Center, School of Nutrition & Food Science, Tabriz University of Medical Sciences, Tabriz, Iran
4Department of Cardiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5Nutrition Research Center, Department of Clinical Nutrition, School of Nutrition & Food Science, Tabriz University of Medical Sciences, Tabriz, Iran

Original Article

Article info
Article History:
Received: 5 September 2020
Accepted: 24 January 2021
epublished: 18 February 2021

Keywords:
Cardiomyopathy
T2* Magnetic Resonance Imaging
Ferritin
Iron Overload
β-Thalassemia

Abstract
Introduction: In this study, we aimed to assess the relationship of cardiac and hepatic T2* magnetic resonance imaging (MRI) values as a gold standard for detecting iron overload with serum ferritin level, heart function, and liver enzymes as alternative diagnostic methods.

Methods: A total 58 patients with beta-thalassemia major who were all transfusion dependent were evaluated for the study. T2* MRI of heart and liver, echocardiography, serum ferritin level, and liver enzymes measurement were performed. The relationship between T2* MRI findings and other assessments were examined. Cardiac and hepatic T2* findings were categorized as normal, mild, moderate, and severe iron overload.

Results: 22% and 11% of the patients were suffering from severe iron overload in heart and liver, respectively. The echocardiographic findings were not significantly different among different iron load categories in heart or liver. ALT level was significantly higher in patient with severe iron overload than those with normal iron load in heart (P = 0.005). Also, AST level was significantly lower in normal iron load group than mild, moderate, and severe iron load groups in liver (P < 0.05). The serum ferritin level was significantly inversely correlated with cardiac T2* values (r = -0.34, P = 0.035) and hepatic T2* values (r = -0.32, P = 0.001).

Conclusion: Cardiac and hepatic T2* MRI indicated significant correlation with serum ferritin level.

Introduction
β-thalassemia is a hereditary disease resulting from defective hemoglobin production that causes chronic and severe hemolytic anemia.1 Patients with β-thalassemia who need multiple blood transfusions are prone to develop iron overload as a consequence of inadequate chelation therapy, erythrocyte catabolism, hypertransfusion, and excessive iron absorption from the gastrointestinal tract. The heart, liver and various endocrine glands are the major sites for iron deposition that iron overload in these organs induces serious damage to them.2

Iron-induced cardiomyopathy is considered as the most prevalent cause of mortality in patients with thalassemia major which could be reversed if effective chelation therapy is initiated on time.3,4 Moreover, iron storage in hepatocytes, major deposition site for body iron, may develop liver disease as evidenced by increased liver enzymes activity including alkaline phosphatase (ALP), alanine transaminase (ALT), and aspartate aminotransferase (AST).5-6 Therefore, early diagnosis of iron overload in the heart and liver would allow to use appropriate iron-chelating therapy to improve morbidity and increase survival of patients.7

Previous studies reported several methods to evaluate iron burden in patients with thalassemia including total iron binding capacity (TIBC), serum iron, serum ferritin, liver biopsy, echocardiography, and T2* magnetic resonance imaging (MRI).8,9 Some studies indicated that ferritin level is well correlated with iron accumulated in the organs.10,11 but its level may be influenced by inflammatory conditions, infectious, and malignant disease.12 MRI using gradient echo T2* has been identified as a gold standard non-invasive technique to quantify tissue iron levels.13,14 Iron deposited in heart is correlated with cardiac function as assessed by echocardiology.15 Therefore, we aimed to evaluate the cardiac and liver iron deposited using MRI T2* in patients with beta-thalassemia, and to study correlation between MRI T2* outcomes with serum ferritin level, liver...
enzymes activity and also cardiac function measured by echocardiography.

**Materials and Methods**

**Subjects**

This cross-sectional study was carried out on 58 patients with β-thalassemia major who were all transfusion dependent in Shahid Ghazi Tabatabaei Hospital, Tabriz, Iran over November 2011 to October 2016. 43% of patients received desferal, 11% received deferiprone, and 46% received combination of desferal and deferiprone. The patients suffering from β-thalassemia major who were older than 15 years old of age and were transfusion dependent were included in the study. Those patients with valvular heart disease, known history of heart failure, major congenital heart disease and infectious disease were excluded. The patients were also excluded if had not attended regularly and had not consumed their therapy.

**Biochemical measurement**

The activity of ALT, AST, and AL enzymes was evaluated using colorimetric method by commercial kits (Randox, Crumlin, UK). Hemoglobin level were also measured by cyanmethemoglobin method.

**Magnetic resonance imaging**

Cardiac and liver MRI T2* assessment was performed using a 1.5 Tesla MRI device (Magnetom Simphony; Siemens, Erlangen, Germany) to assess the quantity of iron deposition in heart and liver tissue. The T2* MRI values were calculated by “CMR Tools” software (London, UK).16 The patients were classified as normal myocardium if cardiac T2* MRI values were > 20 ms, mild heart iron overload if they were 15-20 ms, moderate heart iron overload if they were 10-15 ms, and severe heart iron overload if they were < 10 ms.17 Cardiac MRI T2* was performed for 46 patients (31 males, 15 females). Based on hepatic T2* image values, the level of iron overload severity in liver were reported in four classes: normal (T2* > 6.3 ms), mild (T2* 2.8-6.3 ms), moderate (T2* 1.4-2.8 ms), and severe (T2* <1.4 ms).18 Forty-five patients (30 males, 15 females) underwent hepatic MRI T2* examination.

**Serum ferritin level**

Serum ferritin level was measured by human ELISA kit (Thermo Fisher, Vilnius, Lithuania). The color changes were detected at wavelength 450 nm using an ELISA microplate reader 2100 Stat Fax (Awareness Technology, Inc., USA) based on the instructions provided by the manufacturer.

**Echocardiography**

Two-dimension (2D), M mode, color Doppler and Tissue Doppler Imaging (TDI) echocardiography was performed using Vivid 7 Dimension (GE Healthcare, USA) with a 2.5 or 3.5 MHz phased array transducer. In all patients, echocardiography was performed after receiving the packed cell and correcting the hemoglobin level. The measurement of the left ventricular diastolic function (LVDF), the left ventricular systolic function (LVSF), the right ventricular systolic function (RVSF), and the pulmonary arterial pressure (PAP) was conducted according to the recommendation of the American Society of Echocardiography (ASE).19 Echocardiographic assessment was performed by an expert cardiologist who was not aware of T2* values and serum ferritin level on 53 patients with β-thalassemia major (37 males, 16 females).

**Statistical analysis**

Data were analyzed using SPSS software version 16 (SPSS Inc., USA). The data distribution was assessed visually and using the Kolmogorov–Smirnov goodness of fit. The results were reported as number (percentage) for categorical variables, as mean ± standard deviation (SD) for normally distributed variables, and as median (interquartile range (IQR)) for non-normally distributed variables. To assess the correlation of liver and cardiac T2* with serum ferritin level the Spearman’s tests were used. Moreover, we used one-way analysis of variance (ANOVA) and Kruskal-Wallis test to compare the serum ferritin, cardiac function, liver enzymes, and hemoglobin level between the cardiac or liver iron load categories for normal and non-normal data, respectively. Post hoc paired comparisons were performed by a Mann-Whitney U test for normal distributed data and by a Sidak test for non-normal distributed data. Categorical data were compared using the chi-square and Fisher exact test. We used the independent-sample t-test to assess the differences in HB level between two categories of LVSF (preserved, reduced), RVSF (preserved, reduced) and PAP (preserved, increased). A P <.05 was as the threshold value of statistical significance.

**Results**

**Characteristics of patients**

We studied 58 patients with β-thalassemia major who were transfusion dependent. The general characteristics of the patients are shown in Table 1. Forty patients (69.0%) were male and the median (IQR) of the patients age was 22 y (20 to 25 year). According to the echocardiography results, cardiac function was normal in the most of the patients; 46 patients (87%) revealed preserved LVDF, 51 patients (96%) indicated preserved RVSF, 52 patients (98%) had normal LVDF, and 41 patients (77%) showed normal PAP. Moreover, the MRI T2* results indicated that the median (IQR) of iron overload in heart and liver was 16.9 ms (10.2 to 25.3 ms) and 2.4 ms (1.8 to 4.3 ms), respectively. Ten (22%) patients were assigned to the severe iron overload in myocardium tissues and 5 (11%) patients were assigned to the severe iron overload in hepatic tissues.

The HB level of patients was not different between two categories of LVSF and RVSF and PAP (data was not ...
The patients were divided to four categories of iron load in heart based on myocardium T2* results as normal, mild, moderate, and severe iron load. The mean MRI T2* times was significantly different among four groups. As shown in Table 2, there were not significant differences among four iron overload groups regarding sex, diabetes mellitus, serum ferritin level, ejection fraction (EF) cardiac function parameters (LVSF, RVSF, PAP), AST level, ALP level, total bilirubin, direct bilirubin, and hemoglobin level. However, the ALT level was significantly different among groups. Post Hoc Mann-Whitney U test paired comparisons indicated that patient with severe iron load had significantly higher ALT level than patients with normal iron load (P=0.005).

Furthermore, there was a significant inverse linear correlation between serum ferritin level and heart MRI T2* (r = -0.34, P=0.035) (Figure 1).

**Hepatic MRI T2**

Based on the results of liver T2*, patients were categorized to four groups including normal, mild, moderate, and severe iron load. In Table 3, the results of comparison of sex, having diabetes mellitus, cardiac function and liver enzymes among four groups of patients with β-thalassemia with different levels of iron overload according to hepatic T2 MRI were shown. The hepatic T2* times showed significantly different values among four groups of patients. The patients in four categories of iron deposition in liver did not show significantly different sex, having diabetes mellitus, EF, cardiac function (LVSF, RVSF, PAP), ALT level, ALP level, total bilirubin, direct bilirubin, and hemoglobin level. However, serum ferritin level was significantly different among groups of patients. Post Hoc Sidak test paired comparisons showed that in patient with normal iron load, serum ferritin level was significantly lower than patients with moderate and severe iron load, as well as, patients with mild iron load had significantly lower serum ferritin than patient with moderate and severe iron load. Moreover, there was significantly different AST level among patients in groups, which in normal iron load group, AST level was significantly lower than mild, moderate and severe iron load groups according to the post Hoc Mann-Whitney U test paired comparisons.

Furthermore, liver MRI T2* was negatively associated with serum ferritin level (r = -0.52, P=0.001) (Figure 2).

**Discussion**

The present study examined the iron overload status using shown).
Iron overload & cardiac/liver T2* in β-thalassemia

J Cardiovasc Thorac Res, 2021, 13(1), 54-60

Cardiac iron load

| Variables                        | Normal              | Mild                | Moderate           | Severe              | P      |
|----------------------------------|---------------------|---------------------|--------------------|---------------------|--------|
| T2*, mean ± SD, ms               | 27.7 ± 5.5          | 17.5 ± 1.8          | 12.6 ± 1.2         | 7.9 ± 1.2           | <0.001 |
| Gender n (%)                     |                     |                     |                    |                     |        |
| Male                             | 12 (60.0)           | 4 (80.0)            | 9 (81.8)           | 6 (60.0)            | 0.578  |
| Female                           | 9 (40.0)            | 1 (20.0)            | 2 (18.2)           | 4 (40.0)            |        |
| Diabetes mellitus, n (%)         |                     |                     |                    |                     |        |
| Yes                              | 3 (16.7)            | 2 (40)              | 5 (50.0)           | 1 (10.0)            | 0.132  |
| No                               | 15 (83.3)           | 3 (60.0)            | 5 (50.0)           | 9 (90.0)            |        |
| Ferritin, median (IQR), ng/mL    | 2440.0 (1747.0-4150.0) | 4570.0 (2378.5-5514.5) | 2554.0 (1828.0-9500.0) | 5134.0 (2862.7-8942.5) | 0.060  |
| EF (%)                           | 55.0 (55.0-60.0)    | 55.0 (27.5-57.5)    | 57.5 (53.7-60.0)   | 55.0 (55.0-60.0)    | 0.527  |
| LVSF n (%)                       |                     |                     |                    |                     |        |
| Preserved                        | 15 (88.2)           | 3 (75.0)            | 8 (72.7)           | 10 (100.0)          | 0.252  |
| Reduced                          | 2 (11.8)            | 1 (25.0)            | 3 (27.3)           | 0                   |        |
| RVSF n (%)                       |                     |                     |                    |                     |        |
| Preserved                        | 17 (100.0)          | 3 (75.0)            | 11 (100.0)         | 10 (100.0)          | 0.095  |
| Reduced                          | 0                   | 1 (25.0)            | 0                  | 0                   |        |
| PAP n (%)                        |                     |                     |                    |                     |        |
| Preserved                        | 11 (64.7)           | 3 (75.0)            | 9 (81.8)           | 10 (100.0)          | 0.181  |
| Increased                        | 6 (35.3)            | 1 (25.0)            | 2 (18.2)           | 0                   |        |
| AST, median (IQR), u/L           | 29.0 (18-37)        | 42.5 (39.2-65.2)    | 40.0 (21.7-56)     | 45.0 (34.5-77.5)    | 0.068  |
| ALT, median (IQR), u/L           | 21.0 (18.0-51.0)    | 53.0 (42.7-64)      | 35.0 (21.5-62.2)   | 60 (54.5-90)        | 0.024  |
| ALP, median (IQR), u/L           | 277.0 (247.0-519.0) | 343.0 (156.0-650)   | 345.0 (286.0-581.0)| 227.0 (155.7-322.5)| 0.142  |
| Bilirubin total, median (IQR), mg/dL | 2.3 (1.5-3.1) | 5.7 (1.2-5.7) | 2.0 (1.6-3.4) | 2.1 (1.8-2.7) | 0.837  |
| Bilirubin direct, median (IQR), mg/dL | 0.3 (0.2-0.5) | 0.3 (0.2-0.3) | 0.3 (0.2-0.4) | 0.3 (0.2-0.3) | 0.778  |
| Hemoglobin, median (IQR), mg/dL  | 9.4 (9.0-10.0)   | 10.0 (9.2-10.7)     | 9.9 (8.3-11.0)     | 9.1 (8.6-9.7)       | 0.408  |

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; EF: ejection fraction; IQR, interquartile range; LVSF: left ventricular systolic function; PAP, pulmonary arterial pressure; RVSF: right ventricular systolic function; SD, standard deviation

*ANOVA test
#Fisher exact test
δKruskal-Wallis test

Cardiac and liver MRI T2* in patients with β-thalassemia major. The relationship between T2* results with serum ferritin level, heart function, and liver enzymes activity was also studied. Based on the MRI T2* times, 22% percent and 11% of the patients were suffering from severe iron overload in heart and liver, respectively. Comparison of different categories of heart iron load indicated that only ALT activity was higher in patient with severe iron load than patients with normal iron load. Whilst, serum ferritin and AST levels was significantly different among hepatic iron load categories. There was a significant inverse correlation between serum ferritin level and cardiac iron load and hepatic iron load as well.

Until the development of cardiac and liver MRI techniques in the 2000s, liver biopsy was the principle standard method to assess the body iron burden. However, since liver biopsy is an expensive, unpleasant, and invasive procedure which has inter-observer inconsistency and sampling error because of intra-organ variability in hepatic iron content, its use has been limited. T2* MRI is a noninvasive technique for quantification of iron overload in various organs, particularly the liver and the heart in thalassemia major patients.16,20 This method is
Table 3. Comparison of sex, having diabetes mellitus, cardiac function and liver enzymes among four groups of patients with β-thalassemia with different levels of iron deposition according to hepatic T2’ MRI

| Variables                          | Normal (Normal) | Mild (Mild) | Moderate (Moderate) | Severe (Severe) | P         |
|------------------------------------|----------------|------------|--------------------|----------------|-----------|
| T2’ median (IQR), ms               | 8.7 (7.1-15.4) | 3.4 (3.2-5.2)| 2.0 (1.6-2.4)      | 1.3 (1.0-1.3)  | <0.001a   |
| Gender, n (%)                      |                |            |                    |                |           |
| Male                               | 5 (50.0)       | 6 (80.0)   | 12 (60.0)          | 5 (100.0)      | 0.177a    |
| Female                             | 5 (50.0)       | 2 (20.0)   | 8 (40.0)           | 0              |           |
| Diabetes mellitus, n (%)           |                |            |                    |                |           |
| Yes                                | 1 (11.1)       | 2 (25.0)   | 5 (25.0)           | 3 (60.0)       | 0.317a    |
| No                                 | 8 (88.9)       | 6 (75.0)   | 15 (75.0)          | 2 (40.0)       |           |
| Ferritin, mean ± SD, ng/mL         | 2327.7 ± 1672.5| 2755.1 ± 1176.7 | 5034.5 ± 3028.8   | 6103.6 ± 3495.4 | 0.009a   |
| EF (%)                             | 55.0 (45.0-60.0)| 55.0 (50.0-60.0)| 55.0 (55.0-60.0) | 55.0 (55.0-60.0) | 0.615   |
| LVSF, n (%)                        |                |            |                    |                |           |
| Preserved                          | 8 (80.0)       | 6 (85.7)   | 16 (84.2)          | 5 (100.0)      | 0.925a    |
| Reduced                            | 2 (20.0)       | 1 (14.3)   | 3 (15.8)           | 0              |           |
| RVSF, n (%)                        |                |            |                    |                |           |
| Preserved                          | 10 (100.0)     | 7 (100.0)  | 18 (94.7)          | 5 (100.0)      | 1.000*    |
| Reduced                            | 0              | 0          | 1 (5.3)            | 0              |           |
| PAP, n (%)                          |                |            |                    |                |           |
| Preserved                          | 6 (80.0)       | 7 (100.0)  | 14 (73.7)          | 5 (100.0)      | 0.169a    |
| Increased                          | 4 (40.0)       | 0          | 5 (28.3)           | 0              |           |
| AST, median (IQR), u/L             | 21.0 (14.2-29.7)| 37.0 (23.0-61.5)| 40.5 (28.5-66.5) | 40.0 (39.5-70.0)| 0.032a   |
| ALT, mean ± SD, u/L                | 21.6 ± 9.1     | 49.6 ± 34.9| 55.7 ± 36.1        | 49.4 ± 18.4    | 0.091*    |
| ALP, median (IQR), u/L             | 222.5 (171.0-584.7) | 490.0 (253.0-552.0) | 299.0 (231.0-408.7) | 343.0 (193.0-503.5) | 0.563a    |
| Bilirubin total, median (IQR), mg/dL | 2.0 (1.4-4.9)   | 2.3 (1.2-4.9) | 2.6 (1.8-3.6)     | 2.0 (1.6-4.0)  | 0.907*    |
| Bilirubin direct, median (IQR), mg/dL | 0.3 (0.2-0.3)  | 0.4 (0.1-0.5) | 0.3 (0.2-0.4)   | 0.3 (0.2-0.4)  | 0.980*    |
| Hemoglobin, mean ± SD, mg/dl       | 9.9 ± 0.9      | 9.7 ± 0.8  | 9.6 ± 1.3          | 8.2 ± 1.3      | 0.061*    |

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate aminotransferase; EF: ejection fraction; IQR, interquartile range; LVSF, left ventricular systolic function; PAP, pulmonary arterial pressure; RVSF, right ventricular systolic function; SD, standard deviation

* ANOVA test
* Fisher exact test
* Kruskal-Wallis test

rapid, simple, and highly reproducible which measures magnetic relaxation properties of each tissue and is inversely associated with intracellular iron deposition. Therefore, T2’ MRI is now considered the gold standard in diagnosis and monitoring of body iron load status and also in the prediction of cardiac failure in patients with thalassemia major. Some previous studies reported that cardiac and hepatic iron overload estimated by T2’ MRI is correlated with serum ferritin level in thalassemia patients, although the results are inconsistent. Our finding that showed a significant correlation between liver and heart T2’ values and serum ferritin measurements are in keeping with the results of Fischer et al and Voskaridou et al, but in contrast to those indicated by Anderson et al who could not find a significant correlation. Karakas et al also found that serum ferritin level was significantly correlated with liver T2’ values, but not with heart T2’ values. Although, serum ferritin level is the most widely used indirect estimate of iron stores in the body in patients with β-thalassemia, the usefulness of this indicator of body iron is limited by the presence of several clinical conditions including infection, inflammation, and liver disease. So, the inconsistent results may be attributed to coexistence condition that affects the ferritin level and also different sensitivity of MRI T2’ for different forms of iron.

Cardiomyopathy due to iron overload is the most common death cause in thalassemia major patients. Tissue Doppler echocardiography could help to detect wall motion abnormalities, as an early sign of cardiac dysfunction in patients with thalassemia. In this study, RVSF, LVSF, and PAP was not significantly different among iron load categories based on cardiac and liver T2’ values, this is similar to results of Moussavi et al, who could not find any significant correlation between MRI finding and cardiac function. However, our results are in contrast to those of Anderson et al and Voskaridou et al, who reported correlation of myocardial T2’ values with left ventricular ejection fraction (LVEF). The cardiac function was normal in most of our patients (above 77% of patients) even in patients with severe iron overload, this may due to late appearance of echocardiographic abnormalities. Meanwhile, two patients with reduced LVSF had normal cardiac and hepatic T2’ MRI. However, lack of the cardiac...
function differences between iron load categories do not decrease the value of measuring cardiac function in combination of MRI T2* because echocardiography could detect patients with advances disease that need emergency cardiac care.

Lever disease, due to iron overload, is the common complication in thalassemia patients that may manifest by increased ALT and AST level. In the present study, ALT level was significantly higher in patients with severe cardiac iron overload than patients with normal cardiac iron overload. Moreover, AST level was significantly different among patients with different hepatic iron load. Mohammad et al who examined the liver functions in thalassemia patients, found that there was a significant positive correlation between serum ferritin and ALT level.30 In a study by Ameli et al, serum ferritin level was significantly greater in patients with ALT level > 40 U/L than patients with ALT level < 40 U/L.31 In our study, we also found that serum ferritin level was significantly correlated to ALT and AST level (data not shown).

Although, to best our knowledge this is the first study that evaluated the association between liver function and T2* MRI results, the correlation between serum ferritin level and liver enzymes, as well as, the correlation between serum ferritin level and T2* MRI values is shown in other studies.32-35 Therefore, assessment of liver enzymes activity may help to estimate the risk of iron load in thalassemia patients.

This study had some limitations. One of the limitations of this study was that the cross-sectional design which precludes to follow the patients and determine the efficient chelation therapy protocols. Moreover, sample size was relatively small and hepatic iron content was not measured by liver biopsy due to high level of discomfort and funding constraint as well. Another limitation of this study was that we do not consider the diseases can affect the liver enzymes such as hereditary and acquired disease of liver.

**Conclusion**

We evaluated the iron load of heart and liver in patients with β-thalassemia major using T2* MRI as a gold standard. Results of cardiac and hepatic T2* MRI showed a significant negative correlation with serum ferritin level. There was not any significant correlation between T2* MRI values and echocardiography results. Moreover, ALT and AST level was significantly different among different cardiac iron load groups and hepatic iron load groups, respectively. Further prospective studies with large sample size are suggested to monitor patients with β-thalassemia major using T2* MRI along with serum ferritin level and liver enzymes.

**Acknowledgements**

The authors thank all the patients who participated in the study.

---

**Competing interest**

The authors declared that there is no conflict of interest.

**Ethical approval**

The Ethics Committee of Tabriz University of Medical Sciences approved this study (reference number: 9410350), and all patients were asked to sign a written informed consent.

**Funding**

None.

**References**

1. Rund D, Rachmilewitz E. Beta-thalassemia. *N Engl J Med.* 2005;353(11):1135-1146. doi:10.1056/NEJMoa050946
2. Borgna-Pignatti C, Galanello R. Thalassemias and related disorders: quantitative disorders of hemoglobin synthesis. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, eds. *Wintrobe’s Clinical Hematology.* Philadelphia: Lippincott Williams & Wilkins; 2004. p. 1319-1365
3. Halalis G, Alexopoulos D, Kremastinos DT, Zombos NC. Heart failure in beta-thalassemia syndromes: a decade of progress. *Am J Med.* 2005;118(9):957-967. doi:10.1016/j.amjmed.2005.02.021
4. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. *Haematologica.* 2007;92(5):658-665. doi:10.3324/haematol.10915
5. Perifanis V, Tziomalos K, Tsatra J, Karyda S, Patsiaoura K, Athanassiou-Metaxa M. Prevalence and severity of liver disease in patients with beta thalassemia major. A single-institution fifteen-year experience. *Haematologica.* 2005;90(8):1136-1138.
6. Bonkovsky HL. Iron and the liver. *Am J Med Sci.* 1991;301(1):32-43. doi:10.1097/00000441-199101000-00006
7. Cappellini MD, Cohen A, Eleftheriou A, Piga A, Porter J, Taher A. *Guidelines for the Clinical Management of Thalassaemia.* Nicosia, CY: Thalassaemia International Federation; 2008.
8. Yuksel IO, Koklu E, Kurtoglu E, Arslan S, Cagirci G, Karakus V, et al. The association between serum ferritin level, tissue Doppler echocardiography, cardiac T2* MRI, and heart rate recovery in patients with beta thalassemia major. *Acta Cardiol Sin.* 2016;32(2):231-238. doi:10.6515/ac20150824a
9. Shamsian BS, Esfahani SA, Milani H, Akhlaghpoo S, Mojtahedzadeh S, Karimi A, et al. Magnetic resonance imaging in the evaluation of iron overload: a comparison of MRI, echocardiography and serum ferritin level in patients with β-thalassemia major. *Clin Imaging.* 2012;36(5):483-488. doi:10.1016/j.clinimag.2011.11.029
10. Olivieri NF, Brittenham GM, Matsui D, Berkovich M, Blendis LM, Cameron RG, et al. Iron-chelation therapy with oral deferoxiprone in patients with thalassemia major. *N Engl J Med.* 1995;332(14):918-922. doi:10.1056/nejm199504063321404
11. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. *Blood.* 1997;89(3):739-761.
12. Puliyel M, Spoerto R, Berdoukas VA, Hofstra TC, Nord A, Carson S, et al. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload. *Am J Hematol*. 2014;89(4):391-394. doi:10.1002/ajh.23650

13. Wood JC. Use of magnetic resonance imaging to monitor iron overload. *Hematol Oncol Clin North Am*. 2014;28(4):747-764. vii. doi:10.1016/j.hoc.2014.04.002

14. Mavrogeni SI, Markusis V, Kaklamanis L, Tsiapras D, Paraskevaidis I, Karavolias G, et al. A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with beta-thalassemia major. *Eur J Haematol*. 2005;75(3):241-247. doi:10.1111/j.1600-0609.2005.00474.x

15. Peng CT, Tsai CH, Wu KH, Hsu CC, Sheng TY. Improvement of cardiac function in thalassemia patients using deferasirox. *Tzu Chi Med J*. 2007;19(4):192-199. doi:10.1016/s1016-3190(10)60016-x

16. Anderson LJ, Holden S, Davis B, Prescott E, Charrrier CC, Bunce NH, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *Eur Heart J*. 2001;22(23):2171-2179. doi:10.1053/euhj.2001.2822

17. Wood JC. Impact of iron assessment by MRI. *Hematology Am Soc Hematol Educ Program*. 2011;2011:443-450. doi:10.1182/asheducation-2011.1.443

18. Labranche R, Gilbert G, Cerny M, Vu KN, Soulhières D, Olivier D, et al. Liver iron quantification with MR imaging: a primer for radiologists. *Radiographics*. 2018;38(2):392-412. doi:10.1148/rg.2018170079

19. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. *J Am Soc Echocardiogr*. 2005;18(12):1440-1463. doi:10.1016/j.echo.2005.10.005

20. Kolnagou A, Fessas C, Papatyrrponas A, Economides C, Kontoghiorghes GJ. Prophylactic use of deferiprone (L1) and magnetic resonance imaging T2* or T2 for preventing heart disease in thalassaemia. *Br J Haematol*. 2004;127(3):360-361; author reply 361-362. doi:10.1111/j.1365-2141.2004.05195.x

21. Anderson LJ. Assessment of iron overload with T2* magnetic resonance imaging. *Prog Cardiovasc Dis*. 2011;54(3):287-294. doi:10.1016/j.pcad.2011.07.004

22. Auger D, Prenell DJ. Cardiac complications in thalassemia major. *Ann N Y Acad Sci*. 2016;1368(1):56-64. doi:10.1111/nyas.13026

23. Chouliaras G, Berdoukas V, Ladis V, Kattamis A, Chatziliami A, Fragodimitri C, et al. Impact of magnetic resonance imaging on cardiac mortality in thalassemia major. *J Magn Reson Imaging*. 2011;34(1):56-59. doi:10.1002/jmri.22621

24. Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. Advances in iron overload therapies, prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. *Curr Med Chem*. 2005;12(23):2663-2681. doi:10.2174/092986705774463003

25. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with beta-thalassaemia major: application of SQUID biomagnetic liver susceptometry. *Br J Haematol*. 2003;121(6):938-948. doi:10.1046/j.1365-2141.2003.04297.x

26. Voskaridou E, Douskou M, Terpos E, Papaistoriou I, Stamoulakatou A, Ourailidis A, et al. Magnetic resonance imaging in the evaluation of iron overload in patients with beta-thalassemia and sickle cell disease. *Br J Haematol*. 2004;126(5):736-742. doi:10.1111/j.1365-2141.2004.05104.x

27. Karakas Z, Yilmaz Y, Bayramoglu Z, Karaman S, Aydogdu S, Karagoe AO, et al. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. *Radiol Med*. 2018;123(8):572-576. doi:10.1007/s11547-018-0889-0

28. Chapman RW, Hussain MA, Gorman A, Laulicht M, Politis D, Flynn DM, et al. Effect of ascorbic acid deficiency on serum ferritin concentration in patients with beta-thalassaemia major and iron overload. *J Clin Pathol*. 1982;35(5):487-491. doi:10.1113/jcp.35.5.487

29. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. *N Engl J Med*. 1974;290(22):1213-1216. doi:10.1056/nejm197405302902201

30. Borgna-Pignotti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberti MR, et al. Survival and complications in thalassemia. *Ann N Y Acad Sci*. 2005;1040-40-47. doi:10.1196/annals.1345.006

31. Vogel M, Anderson LJ, Holden S, Deanfield JE, Prenell DJ, Walker JM. Tissue Doppler echocardiography in patients with thalassaemia detects early myocardial dysfunction related to myocardial iron overload. *Eur Heart J*. 2003;24(1):113-119. doi:10.1016/s0195-668x(02)00381-0

32. Moussavi F, Aliyari Ghasabeh M, Roodpeyma S, Alavi S, Shaki A, Mgehratmand R, et al. Optimal method for early detection of cardiac disorders in thalassemia major patients with beta-thalassaemia major: magnetic resonance imaging or echocardiography? *Blood Res*. 2014;49(3):182-186. doi:10.5045/br.2014.49.3.182

33. Mohammad II, Al-Doski FS. Assessment of liver functions between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. *Saudi Med J*. 2008;29(11):1611-1615.